Replimune Group, Inc. (REPL) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $8.82 (-1.51%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Nov 3, 2025 | Evan Seigerman | BMO Capital | $11.00 | +24.6% |
| Jan 22, 2025 | Evan Seigerman | BMO Capital | $27.00 | +205.9% |
| Dec 3, 2024 | Roger Song | Jefferies | $19.00 | +115.3% |
| Jun 7, 2024 | Robert Burns | H.C. Wainwright | $17.00 | +92.6% |
| Jun 4, 2024 | Peter Lawson | Barclays | $13.00 | +47.3% |
| May 17, 2024 | Evan Seigerman | BMO Capital | $14.00 | +58.6% |
Top Analysts Covering REPL
REPL vs Sector & Market
| Metric | REPL | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 3.11 | 2.24 | 2.40 |
| Analyst Count | 9 | 8 | 19 |
| Target Upside | +57.8% | +11475.0% | +17.1% |
| P/E Ratio | -0.75 | 3.91 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2027-03-31 | $11M | $11M | $11M | 5 |
| 2028-03-31 | $10M | $10M | $10M | 5 |
| 2028-06-30 | $18M | $83M | $193M | 1 |
| 2028-09-30 | $20M | $91M | $211M | 1 |
| 2028-12-31 | $21M | $98M | $226M | 1 |
| 2029-03-31 | $22M | $102M | $236M | 2 |
| 2029-06-30 | $24M | $109M | $254M | 1 |
| 2029-09-30 | $26M | $117M | $271M | 1 |
| 2029-12-31 | $27M | $123M | $285M | 2 |
| 2030-03-31 | $28M | $127M | $294M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2027-03-31 | $-2.06 | $-1.63 | $-0.99 | 5 |
| 2028-03-31 | $-1.65 | $-0.91 | $-0.27 | 5 |
| 2028-06-30 | $-0.08 | $-0.03 | $0.00 | 2 |
| 2028-09-30 | $-0.00 | $0.01 | $0.04 | 2 |
| 2028-12-31 | $-0.00 | $0.05 | $0.13 | 3 |
| 2029-03-31 | $-0.00 | $0.06 | $0.16 | 2 |
| 2029-06-30 | $-0.00 | $0.09 | $0.26 | 1 |
| 2029-09-30 | $-0.00 | $0.13 | $0.35 | 1 |
| 2029-12-31 | $-0.00 | $0.15 | $0.42 | 2 |
| 2030-03-31 | $-0.00 | $0.14 | $0.39 | 2 |
Frequently Asked Questions
What is the analyst consensus for REPL?
The consensus among 9 analysts covering Replimune Group, Inc. (REPL) is Hold with an average price target of $14.00.
What is the highest price target for REPL?
The highest price target for REPL is $27.00, set by Evan Seigerman at BMO Capital on 2025-01-22.
What is the lowest price target for REPL?
The lowest price target for REPL is $11.00, set by Evan Seigerman at BMO Capital on 2025-11-03.
How many analysts cover REPL?
9 analysts have issued ratings for Replimune Group, Inc. in the past 12 months.
Is REPL a buy or sell right now?
Based on 9 analyst ratings, REPL has a consensus rating of Hold (3.11/5) with a +57.8% upside to the consensus target of $14.00.
What are the earnings estimates for REPL?
Analysts estimate REPL will report EPS of $-1.63 for the period ending 2027-03-31, with revenue estimated at $11M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.